• M. Uma
• H. Hohanakrishnan
• N. Karthick

Canine Parvovirus -2 (CPV – 2) is one of the most commonly occurring viral disease of young dogs less than 2 months old causing high morbidity and mortality rate. Only supportive care is given to the affected animals due to the non-availability of specific antiviral treatment for CPV -2 infections. Hence, there is an urgent need to develop novel approaches for treating the animals. An alternate method of treatment which is specific to any disease is passive immunization with polyclonal antibodies. Considering the advantages of avian egg yolk antibodies (IgY) when compared with the mammalian antibodies, several studies are focused on the use of specific IgY antibodies for passive therapy. The present study has been undertaken with the aim of generation of specific avian egg yolk antibodies (IgY) against CPV – 2 vaccine strain using BOVANS strain of White Leghorn chicken. The kinetics of the purified IgY against CPV -2 by Sodium chloride is determined based on the total protein content and specific CPV -2 antibody HI titer. The purity and the virus neutralization capability of the purified specific IgY was determined by SDS PAGE and by in-vitro assay using A-72 cell line respectively. The HI titer of specific CPV -2 antibody titer in the chicken serum reached maximum (Chicken 1 - 512 & Chicken 2 - 256 HI units) in 30th week of their age and started declining gradually after 32 weeks of age. The HI titer of the purified IgY against CPV – 2 reached maximum at 27th week of age. The titer of specific CPV – 2 antibodies maintained up to 32 weeks and declined gradually from 33 week onwards. The birds were given booster doses intermittently based on the antibody titer to increase its levels in the egg yolk. In-order to maintain a high titer of specific antibodies in the egg yolk against any antigen, the birds shall be administered booster doses of antigen based on the antibody titer. The neutralizing ability of the generated and purified IgY antibodies against the field isolate of CPV -2 strain demonstrated that the generated antibodies can be used for passive therapy by a suitable parenteral route of injection based on the clinical trials.

CPV – 2 Avian IgY antibodies, Canine Parvo Avian Egg yolk (IgY) antibodies, Passive therapy, CPV – 2 HI titer, CPV -2 Neutralization assay

"Generation, Purification and Characterization of Avian Egg yolk antibodies against Canine parvovirus - 2", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 1, page no.e698-e710, January-2022, Available :http://www.jetir.org/papers/JETIR2201498.pdf

"Generation, Purification and Characterization of Avian Egg yolk antibodies against Canine parvovirus - 2", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 1, page no. ppe698-e710, January-2022, Available at : http://www.jetir.org/papers/JETIR2201498.pdf